Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...

A particular protein deficiency that leads to liver and lung damage is currently treatable only with decades-old therapies that all have limitations. Biotech startup AIRNA is part of a field of ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Augmentation therapy increased survival in patients with ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to hepatocellular carcinoma. The disease remains asymptomatic until its final stages ...